| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intracranial Aneurysm | 27 | 2025 | 204 | 4.900 |
Why?
|
| Thrombectomy | 18 | 2025 | 220 | 4.020 |
Why?
|
| Embolization, Therapeutic | 29 | 2024 | 272 | 3.940 |
Why?
|
| Endovascular Procedures | 27 | 2026 | 333 | 3.300 |
Why?
|
| Angiography, Digital Subtraction | 17 | 2024 | 99 | 3.120 |
Why?
|
| Intracranial Arteriovenous Malformations | 15 | 2024 | 120 | 3.090 |
Why?
|
| Stents | 23 | 2022 | 409 | 3.080 |
Why?
|
| Cerebral Angiography | 25 | 2019 | 211 | 3.010 |
Why?
|
| Stroke | 26 | 2025 | 1079 | 2.950 |
Why?
|
| Magnetic Resonance Angiography | 19 | 2024 | 269 | 2.660 |
Why?
|
| Cerebrovascular Disorders | 10 | 2019 | 140 | 2.240 |
Why?
|
| Intracranial Arteriosclerosis | 8 | 2024 | 63 | 2.190 |
Why?
|
| Brain Ischemia | 10 | 2023 | 414 | 2.070 |
Why?
|
| Cerebrovascular Circulation | 12 | 2024 | 239 | 1.770 |
Why?
|
| Imaging, Three-Dimensional | 13 | 2024 | 608 | 1.580 |
Why?
|
| Neuroimaging | 6 | 2019 | 132 | 1.510 |
Why?
|
| Magnetic Resonance Imaging | 19 | 2024 | 3476 | 1.460 |
Why?
|
| Arteriovenous Fistula | 8 | 2016 | 53 | 1.410 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2024 | 58 | 1.290 |
Why?
|
| Surgery, Computer-Assisted | 5 | 2025 | 116 | 1.170 |
Why?
|
| Treatment Outcome | 49 | 2026 | 9099 | 1.110 |
Why?
|
| Middle Aged | 65 | 2026 | 27573 | 1.090 |
Why?
|
| Aged | 52 | 2025 | 20434 | 1.060 |
Why?
|
| Humans | 148 | 2026 | 93515 | 1.060 |
Why?
|
| Computed Tomography Angiography | 4 | 2018 | 164 | 1.040 |
Why?
|
| Male | 87 | 2025 | 44557 | 1.030 |
Why?
|
| Retrospective Studies | 37 | 2025 | 10164 | 0.990 |
Why?
|
| Contrast Media | 9 | 2024 | 988 | 0.980 |
Why?
|
| Female | 85 | 2026 | 48702 | 0.970 |
Why?
|
| Carotid Artery Diseases | 4 | 2019 | 100 | 0.930 |
Why?
|
| Reperfusion | 4 | 2020 | 31 | 0.930 |
Why?
|
| Polyvinyls | 5 | 2013 | 21 | 0.920 |
Why?
|
| Infarction, Middle Cerebral Artery | 3 | 2020 | 54 | 0.890 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2026 | 2585 | 0.890 |
Why?
|
| Registries | 10 | 2025 | 990 | 0.860 |
Why?
|
| Radiography, Interventional | 4 | 2025 | 148 | 0.840 |
Why?
|
| Vasculitis | 1 | 2024 | 40 | 0.830 |
Why?
|
| Neurosurgical Procedures | 9 | 2025 | 351 | 0.820 |
Why?
|
| Aneurysm, Ruptured | 9 | 2024 | 61 | 0.790 |
Why?
|
| Blood Vessel Prosthesis | 7 | 2021 | 242 | 0.780 |
Why?
|
| Vasospasm, Intracranial | 3 | 2011 | 36 | 0.750 |
Why?
|
| Hemodynamics | 7 | 2023 | 713 | 0.730 |
Why?
|
| Catheterization | 3 | 2019 | 218 | 0.720 |
Why?
|
| Adult | 47 | 2025 | 27918 | 0.710 |
Why?
|
| Arteriovenous Malformations | 2 | 2013 | 49 | 0.690 |
Why?
|
| Atherosclerosis | 1 | 2024 | 256 | 0.680 |
Why?
|
| After-Hours Care | 1 | 2021 | 8 | 0.670 |
Why?
|
| Aged, 80 and over | 21 | 2025 | 7061 | 0.660 |
Why?
|
| Cone-Beam Computed Tomography | 3 | 2024 | 72 | 0.640 |
Why?
|
| Intracranial Hemorrhages | 2 | 2018 | 135 | 0.630 |
Why?
|
| Cerebral Arteries | 6 | 2017 | 74 | 0.630 |
Why?
|
| Time-to-Treatment | 2 | 2021 | 140 | 0.620 |
Why?
|
| Vertebral Artery | 3 | 2016 | 28 | 0.590 |
Why?
|
| Catheters | 2 | 2023 | 96 | 0.590 |
Why?
|
| Neutrophils | 1 | 2020 | 324 | 0.580 |
Why?
|
| Lymphocytes | 1 | 2020 | 454 | 0.550 |
Why?
|
| Polymers | 2 | 2021 | 218 | 0.540 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2021 | 178 | 0.540 |
Why?
|
| Aneurysm, False | 2 | 2024 | 52 | 0.530 |
Why?
|
| Carotid Stenosis | 4 | 2022 | 114 | 0.530 |
Why?
|
| Fibrinolytic Agents | 6 | 2025 | 239 | 0.520 |
Why?
|
| Sensitivity and Specificity | 12 | 2019 | 1922 | 0.510 |
Why?
|
| Gadolinium | 2 | 2016 | 95 | 0.510 |
Why?
|
| Carotid Artery, Internal | 3 | 2016 | 69 | 0.500 |
Why?
|
| Reproducibility of Results | 14 | 2024 | 2715 | 0.500 |
Why?
|
| Carotid Artery, Internal, Dissection | 3 | 2014 | 30 | 0.490 |
Why?
|
| Head and Neck Neoplasms | 4 | 2011 | 1073 | 0.490 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 306 | 0.480 |
Why?
|
| Spinal Cord | 3 | 2014 | 241 | 0.480 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2020 | 153 | 0.480 |
Why?
|
| Pseudotumor Cerebri | 1 | 2016 | 12 | 0.480 |
Why?
|
| Radiation Exposure | 1 | 2016 | 25 | 0.470 |
Why?
|
| Radiation Dosage | 2 | 2016 | 229 | 0.470 |
Why?
|
| Tinnitus | 1 | 2016 | 24 | 0.470 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2015 | 17 | 0.470 |
Why?
|
| Perfusion Imaging | 2 | 2018 | 48 | 0.460 |
Why?
|
| Nervous System Diseases | 2 | 2020 | 166 | 0.460 |
Why?
|
| Vertebrobasilar Insufficiency | 3 | 2025 | 19 | 0.450 |
Why?
|
| Brain | 8 | 2023 | 2391 | 0.450 |
Why?
|
| Radiosurgery | 4 | 2024 | 317 | 0.450 |
Why?
|
| Microsurgery | 4 | 2024 | 98 | 0.440 |
Why?
|
| Burnout, Professional | 3 | 2022 | 113 | 0.430 |
Why?
|
| Cerebral Revascularization | 2 | 2014 | 27 | 0.430 |
Why?
|
| Physicians | 5 | 2022 | 682 | 0.400 |
Why?
|
| Vascular Surgical Procedures | 3 | 2009 | 150 | 0.400 |
Why?
|
| Cranial Sinuses | 3 | 2021 | 16 | 0.390 |
Why?
|
| Attitude to Health | 1 | 2014 | 217 | 0.380 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 39 | 0.380 |
Why?
|
| Vertebral Artery Dissection | 2 | 2014 | 20 | 0.380 |
Why?
|
| Image Enhancement | 5 | 2019 | 505 | 0.380 |
Why?
|
| Risk Factors | 11 | 2025 | 5899 | 0.370 |
Why?
|
| Algorithms | 6 | 2024 | 1953 | 0.360 |
Why?
|
| Endarterectomy, Carotid | 2 | 2022 | 75 | 0.350 |
Why?
|
| Carotid Body Tumor | 1 | 2011 | 3 | 0.340 |
Why?
|
| Thrombolytic Therapy | 3 | 2025 | 254 | 0.340 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2011 | 12 | 0.340 |
Why?
|
| Cocaine-Related Disorders | 1 | 2011 | 40 | 0.330 |
Why?
|
| Young Adult | 11 | 2024 | 6930 | 0.320 |
Why?
|
| Hydroxyapatites | 1 | 2010 | 7 | 0.320 |
Why?
|
| Blood Flow Velocity | 8 | 2023 | 179 | 0.320 |
Why?
|
| Molar | 1 | 2010 | 21 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 1053 | 0.320 |
Why?
|
| Oral Surgical Procedures | 1 | 2010 | 19 | 0.320 |
Why?
|
| Hemostasis, Surgical | 1 | 2010 | 23 | 0.320 |
Why?
|
| Hemorrhage | 2 | 2014 | 288 | 0.320 |
Why?
|
| Pilot Projects | 7 | 2025 | 917 | 0.320 |
Why?
|
| Carotid Artery Injuries | 1 | 2010 | 21 | 0.310 |
Why?
|
| Prospective Studies | 9 | 2023 | 4560 | 0.310 |
Why?
|
| Diagnosis, Differential | 7 | 2015 | 1546 | 0.310 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2024 | 1261 | 0.300 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 3830 | 0.300 |
Why?
|
| Central Nervous System Vascular Malformations | 4 | 2018 | 40 | 0.300 |
Why?
|
| Mandible | 1 | 2010 | 126 | 0.290 |
Why?
|
| Job Satisfaction | 2 | 2020 | 80 | 0.290 |
Why?
|
| Intracranial Thrombosis | 2 | 2018 | 31 | 0.290 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2024 | 626 | 0.290 |
Why?
|
| Collateral Circulation | 2 | 2020 | 37 | 0.290 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 2802 | 0.280 |
Why?
|
| Societies, Medical | 4 | 2026 | 621 | 0.280 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2021 | 236 | 0.280 |
Why?
|
| Research Report | 2 | 2021 | 43 | 0.280 |
Why?
|
| Angioplasty | 3 | 2021 | 68 | 0.270 |
Why?
|
| Postoperative Complications | 7 | 2023 | 2562 | 0.270 |
Why?
|
| Adolescent | 13 | 2021 | 9606 | 0.270 |
Why?
|
| Dimethyl Sulfoxide | 3 | 2013 | 41 | 0.270 |
Why?
|
| Diagnostic Imaging | 3 | 2009 | 452 | 0.270 |
Why?
|
| Eye Diseases | 2 | 2005 | 58 | 0.270 |
Why?
|
| Surgical Flaps | 1 | 2010 | 252 | 0.270 |
Why?
|
| Anticoagulants | 3 | 2024 | 457 | 0.270 |
Why?
|
| Brain Neoplasms | 3 | 2026 | 813 | 0.270 |
Why?
|
| Hand | 5 | 1991 | 143 | 0.260 |
Why?
|
| Single-Blind Method | 3 | 2018 | 159 | 0.250 |
Why?
|
| Prevalence | 4 | 2021 | 1321 | 0.250 |
Why?
|
| Pandemics | 3 | 2021 | 873 | 0.250 |
Why?
|
| Cerebral Veins | 3 | 2016 | 29 | 0.240 |
Why?
|
| Fused Kidney | 1 | 2026 | 1 | 0.240 |
Why?
|
| Pyelonephritis, Xanthogranulomatous | 1 | 2026 | 3 | 0.240 |
Why?
|
| Risk Assessment | 6 | 2022 | 2441 | 0.240 |
Why?
|
| Rotavirus | 3 | 1991 | 10 | 0.240 |
Why?
|
| Databases, Factual | 7 | 2025 | 1006 | 0.230 |
Why?
|
| Fractures, Stress | 1 | 2025 | 15 | 0.230 |
Why?
|
| Neurosurgery | 3 | 2020 | 141 | 0.230 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2005 | 2 | 0.220 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 3 | 2009 | 4 | 0.220 |
Why?
|
| Orbital Neoplasms | 1 | 2005 | 16 | 0.220 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 338 | 0.220 |
Why?
|
| Gadolinium DTPA | 2 | 2024 | 233 | 0.220 |
Why?
|
| Lacrimal Apparatus | 1 | 2005 | 11 | 0.220 |
Why?
|
| Eye Neoplasms | 1 | 2005 | 25 | 0.220 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 333 | 0.220 |
Why?
|
| Sacrum | 1 | 2025 | 83 | 0.220 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2026 | 96 | 0.220 |
Why?
|
| Time Factors | 8 | 2025 | 5410 | 0.220 |
Why?
|
| Posture | 1 | 2024 | 123 | 0.210 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2020 | 297 | 0.210 |
Why?
|
| Radiology, Interventional | 3 | 2009 | 62 | 0.210 |
Why?
|
| Hemangioma, Cavernous | 1 | 2005 | 66 | 0.210 |
Why?
|
| Hirudins | 1 | 2024 | 5 | 0.210 |
Why?
|
| Eye | 1 | 2005 | 109 | 0.210 |
Why?
|
| Spinal Fractures | 1 | 2025 | 102 | 0.210 |
Why?
|
| Antithrombins | 1 | 2024 | 19 | 0.210 |
Why?
|
| Multimorbidity | 1 | 2024 | 6 | 0.210 |
Why?
|
| Fatal Outcome | 2 | 2016 | 295 | 0.210 |
Why?
|
| National Health Programs | 1 | 2024 | 18 | 0.210 |
Why?
|
| Medicare | 2 | 2018 | 455 | 0.210 |
Why?
|
| United States | 13 | 2025 | 7622 | 0.200 |
Why?
|
| Decision Support Techniques | 1 | 2025 | 185 | 0.200 |
Why?
|
| Nephrectomy | 1 | 2026 | 293 | 0.200 |
Why?
|
| Balloon Occlusion | 1 | 2023 | 28 | 0.200 |
Why?
|
| Treatment Failure | 2 | 2021 | 292 | 0.200 |
Why?
|
| Heparin | 1 | 2024 | 181 | 0.200 |
Why?
|
| Artifacts | 4 | 2013 | 243 | 0.190 |
Why?
|
| Propensity Score | 1 | 2023 | 178 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 189 | 0.190 |
Why?
|
| Phantoms, Imaging | 4 | 2019 | 484 | 0.190 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 2 | 2015 | 143 | 0.190 |
Why?
|
| Delivery of Health Care | 3 | 2024 | 452 | 0.180 |
Why?
|
| Elective Surgical Procedures | 2 | 2021 | 163 | 0.180 |
Why?
|
| Recombinant Proteins | 1 | 2024 | 988 | 0.180 |
Why?
|
| Peptide Fragments | 1 | 2024 | 470 | 0.180 |
Why?
|
| Machine Learning | 1 | 2025 | 341 | 0.180 |
Why?
|
| Carotid Arteries | 2 | 2021 | 131 | 0.180 |
Why?
|
| Child | 10 | 2021 | 7355 | 0.170 |
Why?
|
| Cohort Studies | 9 | 2023 | 3054 | 0.170 |
Why?
|
| Regional Blood Flow | 2 | 2019 | 186 | 0.170 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2021 | 11 | 0.170 |
Why?
|
| Embolic Protection Devices | 1 | 2021 | 9 | 0.170 |
Why?
|
| Data Accuracy | 1 | 2021 | 32 | 0.170 |
Why?
|
| Embolism | 1 | 2021 | 32 | 0.170 |
Why?
|
| Hospitals, Community | 1 | 2021 | 33 | 0.170 |
Why?
|
| Neck | 2 | 2013 | 98 | 0.170 |
Why?
|
| Hand Disinfection | 2 | 1991 | 18 | 0.160 |
Why?
|
| Observer Variation | 4 | 2016 | 570 | 0.160 |
Why?
|
| Neurosurgeons | 1 | 2021 | 45 | 0.160 |
Why?
|
| Hydralazine | 1 | 2020 | 21 | 0.160 |
Why?
|
| North America | 1 | 2021 | 195 | 0.160 |
Why?
|
| Spinal Cord Ischemia | 1 | 2020 | 8 | 0.160 |
Why?
|
| Acute Disease | 2 | 2014 | 841 | 0.160 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 394 | 0.160 |
Why?
|
| Patient Readmission | 2 | 2022 | 412 | 0.160 |
Why?
|
| Emergencies | 1 | 2021 | 122 | 0.160 |
Why?
|
| Basilar Artery | 1 | 2020 | 39 | 0.160 |
Why?
|
| Norepinephrine | 1 | 2020 | 169 | 0.160 |
Why?
|
| Conservative Treatment | 1 | 2020 | 25 | 0.160 |
Why?
|
| Combined Modality Therapy | 4 | 2025 | 1723 | 0.160 |
Why?
|
| Permeability | 2 | 2017 | 143 | 0.150 |
Why?
|
| Thoracic Vertebrae | 1 | 2020 | 89 | 0.150 |
Why?
|
| Needles | 2 | 2025 | 39 | 0.150 |
Why?
|
| Robotic Surgical Procedures | 1 | 2026 | 368 | 0.150 |
Why?
|
| Hydrogels | 1 | 2020 | 92 | 0.150 |
Why?
|
| Intracranial Embolism | 1 | 2019 | 29 | 0.150 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 66 | 0.150 |
Why?
|
| Health Expenditures | 2 | 2018 | 102 | 0.150 |
Why?
|
| Computer Graphics | 1 | 2019 | 100 | 0.140 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2011 | 31 | 0.140 |
Why?
|
| Social Media | 1 | 2021 | 111 | 0.140 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2013 | 283 | 0.140 |
Why?
|
| Physician's Role | 1 | 2020 | 176 | 0.140 |
Why?
|
| Embolectomy | 2 | 2015 | 6 | 0.140 |
Why?
|
| Angiography | 3 | 2020 | 192 | 0.140 |
Why?
|
| Preoperative Care | 2 | 2012 | 406 | 0.140 |
Why?
|
| Chicago | 2 | 2021 | 1464 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 759 | 0.140 |
Why?
|
| Vascular Closure Devices | 1 | 2018 | 3 | 0.140 |
Why?
|
| Multimodal Imaging | 2 | 2017 | 109 | 0.140 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 1847 | 0.140 |
Why?
|
| Neuroendoscopy | 1 | 2018 | 20 | 0.130 |
Why?
|
| Escherichia coli | 2 | 1991 | 563 | 0.130 |
Why?
|
| Health Personnel | 1 | 2020 | 234 | 0.130 |
Why?
|
| Intracranial Hypertension | 2 | 2016 | 58 | 0.130 |
Why?
|
| Fluoroscopy | 3 | 2025 | 129 | 0.130 |
Why?
|
| Foreign Bodies | 1 | 2018 | 63 | 0.130 |
Why?
|
| Disease Management | 2 | 2017 | 358 | 0.130 |
Why?
|
| Thrombosis | 1 | 2020 | 309 | 0.130 |
Why?
|
| Neurovascular Coupling | 1 | 2017 | 5 | 0.130 |
Why?
|
| Spinal Diseases | 2 | 2020 | 97 | 0.130 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 64 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2021 | 485 | 0.130 |
Why?
|
| Lumbar Vertebrae | 1 | 2020 | 358 | 0.130 |
Why?
|
| Pia Mater | 1 | 2016 | 10 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 283 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2025 | 1713 | 0.120 |
Why?
|
| Glioblastoma | 1 | 2019 | 281 | 0.120 |
Why?
|
| Patient Selection | 3 | 2021 | 690 | 0.120 |
Why?
|
| Superior Sagittal Sinus | 1 | 2016 | 2 | 0.120 |
Why?
|
| Cerebral Infarction | 1 | 2016 | 73 | 0.120 |
Why?
|
| Arteriosclerosis | 1 | 2016 | 106 | 0.120 |
Why?
|
| Veins | 1 | 2016 | 87 | 0.120 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2016 | 64 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 454 | 0.120 |
Why?
|
| Coronary Circulation | 1 | 2016 | 95 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 660 | 0.110 |
Why?
|
| Asthma | 1 | 2023 | 1039 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1931 | 0.110 |
Why?
|
| Platelet Function Tests | 1 | 2014 | 11 | 0.110 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2015 | 106 | 0.110 |
Why?
|
| Thromboembolism | 2 | 2014 | 122 | 0.110 |
Why?
|
| Capillary Permeability | 1 | 2015 | 131 | 0.110 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 261 | 0.100 |
Why?
|
| Radiography | 2 | 2013 | 790 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2016 | 494 | 0.100 |
Why?
|
| Hoarseness | 1 | 2013 | 11 | 0.100 |
Why?
|
| Biomarkers | 1 | 2020 | 1910 | 0.100 |
Why?
|
| Vocal Cord Paralysis | 1 | 2013 | 25 | 0.100 |
Why?
|
| Syndrome | 2 | 2011 | 437 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 394 | 0.100 |
Why?
|
| Moyamoya Disease | 1 | 2013 | 21 | 0.100 |
Why?
|
| Radiographic Image Enhancement | 1 | 2015 | 449 | 0.100 |
Why?
|
| Platinum | 2 | 2020 | 67 | 0.100 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2015 | 180 | 0.100 |
Why?
|
| Fistula | 1 | 2013 | 42 | 0.100 |
Why?
|
| Ventriculostomy | 1 | 2013 | 23 | 0.100 |
Why?
|
| Vertebroplasty | 1 | 2013 | 16 | 0.090 |
Why?
|
| Competency-Based Education | 1 | 2013 | 37 | 0.090 |
Why?
|
| Qualitative Research | 1 | 2014 | 347 | 0.090 |
Why?
|
| Aortic Coarctation | 1 | 2012 | 31 | 0.090 |
Why?
|
| Illinois | 1 | 2014 | 520 | 0.090 |
Why?
|
| Equipment Design | 3 | 2023 | 416 | 0.090 |
Why?
|
| Astrocytoma | 1 | 2012 | 86 | 0.090 |
Why?
|
| Paramyxoviridae Infections | 1 | 1991 | 5 | 0.090 |
Why?
|
| Common Cold | 1 | 1991 | 13 | 0.090 |
Why?
|
| Disinfection | 1 | 1991 | 16 | 0.090 |
Why?
|
| Rotavirus Infections | 1 | 1991 | 11 | 0.090 |
Why?
|
| Hemostasis | 1 | 2011 | 24 | 0.080 |
Why?
|
| Gastroenteritis | 1 | 1991 | 26 | 0.080 |
Why?
|
| Aging | 1 | 2016 | 727 | 0.080 |
Why?
|
| Injections | 1 | 2011 | 124 | 0.080 |
Why?
|
| Iatrogenic Disease | 1 | 2011 | 69 | 0.080 |
Why?
|
| Length of Stay | 3 | 2015 | 828 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2011 | 135 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 1991 | 110 | 0.080 |
Why?
|
| Postpartum Period | 1 | 2011 | 159 | 0.080 |
Why?
|
| Headache | 1 | 2011 | 75 | 0.080 |
Why?
|
| Injections, Intralesional | 1 | 2010 | 21 | 0.080 |
Why?
|
| Alveolar Bone Loss | 1 | 2010 | 20 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 1991 | 150 | 0.080 |
Why?
|
| Child, Preschool | 4 | 2021 | 3829 | 0.080 |
Why?
|
| Survival Rate | 1 | 2014 | 1948 | 0.080 |
Why?
|
| Recurrence | 3 | 2020 | 1190 | 0.080 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2009 | 5 | 0.080 |
Why?
|
| Anti-Infective Agents, Local | 1 | 1989 | 24 | 0.080 |
Why?
|
| Hospitalization | 1 | 2015 | 937 | 0.080 |
Why?
|
| Neoplasms, Vascular Tissue | 1 | 2009 | 3 | 0.080 |
Why?
|
| Hemostatics | 1 | 2009 | 60 | 0.070 |
Why?
|
| Iohexol | 1 | 2009 | 20 | 0.070 |
Why?
|
| Ambulatory Care | 1 | 2010 | 193 | 0.070 |
Why?
|
| Cerebrovascular Trauma | 1 | 2009 | 9 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2009 | 228 | 0.070 |
Why?
|
| Neuroradiography | 1 | 2008 | 3 | 0.070 |
Why?
|
| Recovery of Function | 2 | 2025 | 342 | 0.070 |
Why?
|
| Incidence | 3 | 2020 | 1701 | 0.070 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 75 | 0.070 |
Why?
|
| Infant | 4 | 2016 | 3220 | 0.070 |
Why?
|
| Disease Progression | 1 | 2013 | 1531 | 0.070 |
Why?
|
| Equipment Contamination | 1 | 1988 | 29 | 0.070 |
Why?
|
| Critical Illness | 1 | 2011 | 343 | 0.070 |
Why?
|
| Head | 1 | 2008 | 131 | 0.070 |
Why?
|
| Anesthesia | 1 | 2010 | 175 | 0.070 |
Why?
|
| Mass Screening | 1 | 2013 | 696 | 0.070 |
Why?
|
| Hospital Mortality | 3 | 2021 | 482 | 0.070 |
Why?
|
| Dogs | 2 | 2020 | 634 | 0.070 |
Why?
|
| Anesthesiology | 1 | 2010 | 167 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1917 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 920 | 0.060 |
Why?
|
| Cerebral Hemorrhage | 1 | 2010 | 367 | 0.060 |
Why?
|
| Brain Injuries | 1 | 2009 | 164 | 0.060 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2006 | 29 | 0.060 |
Why?
|
| Inpatients | 2 | 2022 | 345 | 0.060 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 579 | 0.060 |
Why?
|
| Retroperitoneal Space | 1 | 2026 | 42 | 0.060 |
Why?
|
| Proof of Concept Study | 1 | 2025 | 56 | 0.060 |
Why?
|
| Aneurysm | 2 | 2017 | 57 | 0.060 |
Why?
|
| ROC Curve | 2 | 2019 | 775 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2025 | 171 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2006 | 251 | 0.050 |
Why?
|
| Neurologic Examination | 2 | 2016 | 120 | 0.050 |
Why?
|
| Drug Substitution | 1 | 2024 | 28 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2024 | 148 | 0.050 |
Why?
|
| Australia | 1 | 2024 | 123 | 0.050 |
Why?
|
| Logistic Models | 2 | 2019 | 1243 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2025 | 291 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2021 | 2479 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2023 | 149 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2026 | 404 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2015 | 756 | 0.040 |
Why?
|
| Medical Errors | 1 | 2022 | 94 | 0.040 |
Why?
|
| Spine | 2 | 2013 | 150 | 0.040 |
Why?
|
| Life Cycle Stages | 1 | 2021 | 16 | 0.040 |
Why?
|
| Fatigue | 1 | 2022 | 181 | 0.040 |
Why?
|
| Sleep Deprivation | 1 | 2022 | 125 | 0.040 |
Why?
|
| Accidents, Traffic | 1 | 2022 | 102 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2025 | 1729 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 292 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2017 | 1118 | 0.040 |
Why?
|
| Infarction | 1 | 2020 | 25 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 960 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2020 | 67 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 104 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2020 | 133 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 1906 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 78 | 0.040 |
Why?
|
| Patient Admission | 1 | 2020 | 119 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2019 | 65 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 769 | 0.040 |
Why?
|
| Animals | 5 | 2021 | 28155 | 0.040 |
Why?
|
| Calcinosis | 1 | 2019 | 222 | 0.030 |
Why?
|
| Decision Making | 1 | 2023 | 674 | 0.030 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 147 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2019 | 321 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2019 | 250 | 0.030 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 187 | 0.030 |
Why?
|
| Urban Health Services | 1 | 2017 | 46 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2018 | 118 | 0.030 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2017 | 19 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 1366 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 2016 | 30 | 0.030 |
Why?
|
| Sample Size | 1 | 2017 | 128 | 0.030 |
Why?
|
| Mechanical Thrombolysis | 1 | 2016 | 18 | 0.030 |
Why?
|
| Middle Cerebral Artery | 1 | 2016 | 22 | 0.030 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2016 | 15 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 196 | 0.030 |
Why?
|
| Morbidity | 1 | 2016 | 162 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2016 | 38 | 0.030 |
Why?
|
| Patient Safety | 1 | 2018 | 218 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2016 | 207 | 0.030 |
Why?
|
| Surgical Instruments | 1 | 2015 | 62 | 0.030 |
Why?
|
| Dominance, Cerebral | 1 | 2015 | 60 | 0.030 |
Why?
|
| Microcirculation | 1 | 2015 | 98 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2015 | 116 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 985 | 0.030 |
Why?
|
| Kinetics | 1 | 2017 | 1492 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 754 | 0.030 |
Why?
|
| Motivation | 1 | 2016 | 310 | 0.030 |
Why?
|
| Shear Strength | 1 | 2013 | 17 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1161 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2014 | 233 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2017 | 585 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 86 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 2013 | 92 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 657 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2013 | 67 | 0.020 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2013 | 33 | 0.020 |
Why?
|
| Software | 1 | 2017 | 670 | 0.020 |
Why?
|
| Causality | 1 | 2013 | 82 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2013 | 248 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2013 | 188 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 1105 | 0.020 |
Why?
|
| Magnetic Fields | 1 | 2012 | 12 | 0.020 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 1991 | 2 | 0.020 |
Why?
|
| Disinfectants | 1 | 1991 | 8 | 0.020 |
Why?
|
| Rhinovirus | 1 | 1991 | 29 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2013 | 189 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2013 | 168 | 0.020 |
Why?
|
| Air Microbiology | 1 | 1991 | 5 | 0.020 |
Why?
|
| Water Microbiology | 1 | 1991 | 14 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2013 | 145 | 0.020 |
Why?
|
| Michigan | 1 | 2010 | 55 | 0.020 |
Why?
|
| Pain | 1 | 2013 | 414 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 217 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 449 | 0.020 |
Why?
|
| Soaps | 1 | 1989 | 2 | 0.020 |
Why?
|
| Fresh Water | 1 | 1989 | 22 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 401 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1103 | 0.020 |
Why?
|
| Seasons | 1 | 1991 | 240 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2009 | 26 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 608 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2495 | 0.020 |
Why?
|
| Global Health | 1 | 1991 | 208 | 0.020 |
Why?
|
| Craniotomy | 1 | 2010 | 91 | 0.020 |
Why?
|
| Carotid Artery, External | 1 | 2009 | 9 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2009 | 33 | 0.020 |
Why?
|
| Accidents, Occupational | 1 | 2009 | 8 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1007 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 829 | 0.020 |
Why?
|
| Cavernous Sinus | 1 | 2009 | 15 | 0.020 |
Why?
|
| Emergency Medicine | 1 | 2010 | 136 | 0.020 |
Why?
|
| Steel | 1 | 1988 | 1 | 0.020 |
Why?
|
| Deep Brain Stimulation | 1 | 2010 | 89 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 711 | 0.020 |
Why?
|
| Conjunctivitis, Acute Hemorrhagic | 1 | 1988 | 1 | 0.020 |
Why?
|
| Enterovirus | 1 | 1988 | 16 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 202 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 889 | 0.020 |
Why?
|
| Feces | 1 | 1989 | 360 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1395 | 0.020 |
Why?
|
| Cell Line | 2 | 1988 | 2464 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2013 | 822 | 0.020 |
Why?
|
| Radiology | 1 | 2009 | 192 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 1524 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1914 | 0.020 |
Why?
|
| Spinal Fusion | 1 | 2010 | 347 | 0.010 |
Why?
|
| Skin | 1 | 1988 | 578 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2013 | 1090 | 0.010 |
Why?
|
| Prognosis | 1 | 2010 | 3911 | 0.010 |
Why?
|
| Humidity | 1 | 1988 | 94 | 0.000 |
Why?
|
| Temperature | 1 | 1988 | 424 | 0.000 |
Why?
|
| Models, Biological | 1 | 1988 | 1768 | 0.000 |
Why?
|